Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zenith's tolazamide

Executive Summary

Shipments of the Tolinase generic began Oct. 3 following final FDA approval. Firm said its prices are 50% of Upjohn's direct price to drug stores as listed in the July Redbook. Upjohn figures were $53.51 for 250 mg 200s and $261.25 for 250 mg 1,000s. Zenith said initial shipments of its 100, 250 and 500 mg tolazamide are in excess of $1 mil. A generic version of Pfizer's Diabinese (chlorpropamide) will also be introduced after the patent expires Oct. 24

You may also be interested in...



Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio catch-up on the latest major developments in the global biopharma industry, as reported by 

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel